Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell (NYSE:PFE)
1. Pfizer is rated a sell for the next 18-24 months. 2. Medicare changes could reduce 2025 revenue by $1 billion. 3. Patent expirations for key drugs are expected in 2026. 4. Danuglipron might boost sentiment if late-stage trials succeed in 2025. 5. Shorting PFE is considered to lack good risk-reward.